Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

221.23B

Market cap221.23B

Price-Earnings ratio

11.46

Price-Earnings ratio11.46

Dividend yield

2.52%

Dividend yield2.52%

Average volume

11.30M

Average volume11.30M

High today

$49.64

High today$49.64

Low today

$48.73

Low today$48.73

Open price

$49.17

Open price$49.17

Volume

3.16M

Volume3.16M

52 Week high

$71.80

52 Week high$71.80

52 Week low

$35.12

52 Week low$35.12

NVO News

TipRanks 14m

Novo Nordisk Tests New Obesity Dose Strategy, Keeping Its Pipeline Momentum

Novo Nordisk (NVO) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an ETF b...

TipRanks 20m

Cboe data shows mixed options sentiment in Novo Nordisk with shares up 1.22%

Cboe data shows mixed options sentiment in Novo Nordisk (NVO), with shares up 60c, or 1.22%, near $49.48. Options volume relatively light with 24k contracts tra...

Nasdaq 5h

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week

Key Points Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition...

Analyst ratings

57%

of 37 ratings

Buy

37.8%

Hold

56.8%

Sell

5.4%

More NVO News

Reuters 20h

South African regulators issue recall of Ozempic copies - Reuters

...

The Motley Fool 21h

Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.

GLP-1 drugs are more popular than ever. This week, polling organization Gallup reported that 11% of U.S. adults are currently taking GLP-1 medications for weigh...

TipRanks 1d

Novo Nordisk Halts Device Study for CagriSema: What It Means for NVO Investors

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more...

Simply Wall St 2d

Novo Nordisk Updates Wegovy Label In Singapore With 21% Weight Loss Data

Novo Nordisk has updated the prescribing label for Wegovy in Singapore using new STEP UP trial data. The trial focused on adults with obesity who do not have d...

Nasdaq 3d

Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom

Key Points Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver...

Investor's Business Daily 3d

Eli Lilly's Market Cap Balloons Again On This IPO's Setback

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone 4:30 AM ET Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assig...

Investor's Business Daily 3d

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone

Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants. 5/26/2026 More than 70% of GLP-1 users in the UBS Evidence Lab survey...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.